Back to Journals » OncoTargets and Therapy » Volume 4

OncoTargets and Therapy


Archive: Volume 4, 2011

Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer

Deshpande H, Marler V, Sosa JA

OncoTargets and Therapy 2011, 4:209-215

Published Date: 9 December 2011

Surgical management of retrorectal tumors: a retrospective study of a 9-year experience in a single institution

Lin CZ, Jin KT, Lan HR, Teng LS, Lin JJ, Chen WB

OncoTargets and Therapy 2011, 4:203-208

Published Date: 30 November 2011

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer

Muñoz-Couselo E, Pérez-García J, Cortés J

OncoTargets and Therapy 2011, 4:185-192

Published Date: 14 November 2011

Targeted treatment for chronic lymphocytic leukemia

Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A

OncoTargets and Therapy 2011, 4:169-183

Published Date: 4 November 2011

Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia

Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A

OncoTargets and Therapy 2011, 4:149-168

Published Date: 5 September 2011

Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents

Khan MK, Khan N, Almasan A, Macklis R

OncoTargets and Therapy 2011, 4:137-148

Published Date: 9 August 2011

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval

Yamamoto Y, Kawano I, Iwase H

OncoTargets and Therapy 2011, 4:123-136

Published Date: 18 July 2011

The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine

Ahmad EI, Gawish HH, Al Azizi NMA, Elhefni AM

OncoTargets and Therapy 2011, 4:115-121

Published Date: 15 July 2011

Current therapeutic strategies for invasive and metastatic bladder cancer

Vishnu P, Mathew J, Tan WW

OncoTargets and Therapy 2011, 4:97-113

Published Date: 11 July 2011

Downregulation of CD44 reduces doxorubicin resistance of CD44+CD24- breast cancer cells

Phuc PV, Nhan PLC, Nhung TH, Tam NT, Hoang NM, Tue VG, Thuy DT, Ngoc PK

OncoTargets and Therapy 2011, 4:71-78

Published Date: 21 June 2011

Antioxidant oils and Salmonella enterica Typhimurium reduce tumor in an experimental model of hepatic metastasis

Sorenson BS, Banton KL, Augustin LB, Leonard AS, Saltzman DA

OncoTargets and Therapy 2011, 4:59-69

Published Date: 30 May 2011

Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC

Ballas MS, Chachoua A

OncoTargets and Therapy 2011, 4:43-58

Published Date: 30 May 2011

An update on TroVax® for the treatment of progressive castration-resistant prostate cancer

Abern M, Kaufman HL, Latchamsetty K

OncoTargets and Therapy 2011, 4:33-41

Published Date: 24 May 2011

Expression of organic anion-transporting polypeptides 1B3, 1B1, and 1A2 in human pancreatic cancer reveals a new class of potential therapeutic targets

Kounnis V, Ioachim E, Svoboda M, Tzakos A, Sainis I, Thalhammer T, Steiner G, Briasoulis E

OncoTargets and Therapy 2011, 4:27-32

Published Date: 8 April 2011

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab

Rose JS, Bekaii-Saab TS

OncoTargets and Therapy 2011, 4:21-26

Published Date: 24 March 2011

Electronic brachytherapy as adjuvant therapy for early stage breast cancer: a retrospective analysis

William C Dooley, James C Wurzer, Mohamed Megahy, et al

OncoTargets and Therapy 2011, 4:13-20

Published Date: 12 January 2011

Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection

Carmen Criscitiello, Debora Fumagalli, Kamal S Saini, et al

OncoTargets and Therapy 2011, 4:1-11

Published Date: 17 December 2010